Mutant IDH1 inhibitor
CAS : 1429180-08-4
Ref. 3D-EHC18008
| 1mg | Arrêté | ||
| 5mg | Arrêté | ||
| 10mg | Arrêté | ||
| 25mg | Arrêté | ||
| 50mg | Arrêté |
Informations sur le produit
Mutant IDH1 inhibitors are natural compounds that have been identified as potential biomarkers for cancer. They inhibit the enzyme IDH1 and can be used as a pharmacological treatment for solid tumours. Mutant IDH1 inhibitors are able to reduce the levels of mutant IDH1 enzymes, which are associated with cellular transformation. They have minimal toxicity and can be used in combination with other drugs to prevent relapse of cancer cells. The most common form of this inhibitor is a small molecule that can be detected using an analytical method such as mass spectrometry or nuclear magnetic resonance. These compounds bind to the catalytic site of mutant IDH1 enzymes, inhibiting them from converting glutamate into alpha-ketoglutarate, which is needed for energy production in cells. Researchers have also shown that these inhibitors can slow down tumor growth in mice by interfering with the growth cycle of cancer cells.
